Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA

European Respiratory Journal

Volumn 52, Issue 1, 2018, Pages

  Noth, Imre ^a   Oelberg, David ^b   Kaul, Manika ^c   Conoscenti, Craig S ^c   Raghu, Ganesh ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b DANBURY HOSPITAL   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ADVERSE EVENT; CAUSE OF DEATH; CLINICAL PRACTICE; DIARRHEA; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; HUMAN; INCIDENCE; LETTER; LUNG FIBROSIS; LUNG INSUFFICIENCY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK FACTOR; UNITED STATES; EPIDEMIOLOGY;

ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES;

EID: 85061965627     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.02106-2017     Document Type: Letter

References (14)

1. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV™ (nintedanib) prescribing information, 2017. http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/ PIs/Ofev/ofev.pdf Date last accessed: June 20, 2017.
2. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
3. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985.
4. Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257-1261.
5. Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011; 84: 102-113.
6. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462-467.
7. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012; 15: 829-835.
8. Tam CC, Viviani L, Rodrigues LC, et al. The second study of infectious intestinal disease (IID2): increased rates of recurrent diarrhoea in individuals aged 65 years and above. BMC Public Health 2013; 13: 739.
9. Dalleywater W, Powell HA, Hubbard RB, et al. Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study. Chest 2015; 147: 150-156.
10. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015; 16: 116.
11. Suvarna V. Phase IV of drug development. Perspect Clin Res 2010; 1: 57-60.
12. Talbot JCC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol 1998; 45: 427-431.
13. Food and Drug Administration. Guidance for Industry. Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, 2005. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm071696.pdf Date last accessed: May 5, 2016.
14. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385-396.